Latest B-cell chronic lymphocytic leukemia Stories
New submission based on positive Phase 3 data from the RESONATE(TM) trial RARITAN, N.J., April 8, 2014 /PRNewswire/ -- Janssen Research & Development, LLC ("Janssen") today announced
SUNNYVALE, Calif., April 8, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S.
Kanti Rai, MD, and Jacqueline Barrientos, MD, comment on study of new leukemia therapy. Lake Success, NY (PRWEB) March 20, 2014 Two
NEWTOWN, Pa., March 11, 2014 /PRNewswire/ -- BioClinica®, Inc., a leading provider of specialized outsourced clinical
WASHINGTON, March 10, 2014 /PRNewswire-USNewswire/ -- A pill that suppresses a key regulator of cancer growth may provide hope to relapsed leukemia and lymphoma patients running out of treatment
Over the last decade, much knowledge has been gained regarding the genetic events that drive leukemia; the exact cell of origin, however, remains largely unknown.
A study led by Dr. Roderic Guigó from the Centre for Genomic Regulation in Barcelona, as part of the Chronic Lymphatic Leukaemia Genome Consortium, has made new advances in the study of this disease.
Company launches its first product, IMBRUVICA(TM), and records net product revenue of $13.6 million SUNNYVALE, Calif., Feb. 20, 2014 /PRNewswire/ -- Pharmacyclics, Inc.
Babies who develop leukemia during the first year of life appear to inherit an unfortunate combination of genetic variations that can make the infants highly susceptible to the disease.
FLINT, Mich., Feb. 13, 2014 /PRNewswire-iReach/ -- Diplomat, the country's largest independent specialty pharmacy, announced today that IMBRUVICA(TM) (ibrutinib) was approved by the U.S.
- The governor of a province or people.